

NYRx BLTG Program Update: Flovent and Advair

What Pharmacy Providers and Prescribers Need to Know

Flovent® and **Advair®** products continue to be included in the Brand Less Than Generic Program (BLTG). However, due to recent changes announced by the manufacturer including the discontinuation of Flovent® and the decreased production of Advair®, effective **December 21, 2023**, the NYRx Medicaid Pharmacy Program will allow for the generics to these products to adjudicate without prior authorization. If a pharmacy is unable to obtain Flovent® or Advair® from their wholesaler and the member needs the medication, they may submit for the generic product.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form, and strength as the drug prescribed/ordered. This includes substituting the brand name drug when NYRx has determined it to be the less expensive alternative for the patient. Brand name drugs included in this program:

- Do not require “Dispense as Written” (DAW) or “Brand Medically Necessary” on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

Important Billing Information

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of a DAW Product Selection Code of “1”; Pharmacies should **submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive an NCPDP reject response of “22” which means missing/invalid DAW code if other DAW codes are submitted. The only exceptions to this are DAW code “1” and “Brand Medically Necessary” on the prescription.

For a complete list, see [NYRx BLTG Program Brand Name Drugs](#) on the next page.

NYRx BLTG Drugs

| NYRx BLTG Program Brand Name Drugs* | | |
|-------------------------------------|----------------------|--------------------------|
| Advair Diskus® | Glumetza® | Renvela® tablet |
| Advair HFA® | Kazano® | Restasis® |
| Alphagan P® 0.15% | Kitabis® Pak | Retin-A® cream |
| Amitiza® | Kombiglyze® XR | Ritalin LA® |
| Apriso® | Lialda® | Spiriva® HandiHaler® |
| Azopt™ | Nesina® | Symbicort® |
| Bethkis® | Nexavar® | Tegretol® suspension |
| Cellcept® suspension | NuvaRing® | Tegretol® XR |
| Combigan® | Onglyza® | Trileptal® suspension |
| Copaxone® 20mg SQ | Oseni® | Vascepa® |
| Daytrana® | Pennsaid® pump | Ventolin® HFA |
| Depakote® Sprinkle | Pentasa® | Vyvanse® capsule |
| Dexilant® | Pradaxa® | Vyvanse® chewable tablet |
| Dymista® | Protonix® suspension | Xopenex HFA® |
| Epipen | Pylera® | Zegerid® Rx |
| Epipen JR | Rapamune® solution | |
| Flovent® HFA | Renvela® powder pack | |

* This list is subject to change. For the most recent updates, see the [Brand Less than Generic Program Updates](#).

* Drugs in this program may be subject to prior authorization requirements of other pharmacy programs.

Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Pharmacy Program Preferred Drug List](#)

Contact Information

The NYRx Education & Outreach Call Center is available at 833-967-7310 from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.